Histidine for Health & Longevity - Quick Reference Sheet

Histidine for Health & Longevity

Created on 07/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

An essential amino acid obtained from food and supplements. The most encouraging evidence points to modest gains in blood-sugar control, inflammation, and waist size, with weaker signals for skin and memory and only theoretical longevity support. Well tolerated at modest doses, but the evidence is thin. Avoid in liver disease; watch zinc balance. (Full Review)

Protocol

Standard Dose
4 g/day
Oral L-histidine; general range 0.5–4 g/day
Duration
12 weeks
Best-characterized course; can also be ongoing
Timing
Earlier in day
With or between meals; food if stomach sensitive
Time to effect
Insulin & Blood Sugar
~12 weeks
Metabolic gains accrued in the main trial
Inflammation
~12 weeks
Inflammatory markers fell over the trial
Skin Barrier
Gradual
Not immediate

Benefits

Contraindications
  • Liver disease (cirrhosis, hepatic encephalopathy)
  • Histidinemia
  • Diagnosed histamine intolerance
  • Mast-cell activation syndrome
Key Interactions
  • Zinc, copper & iron supplements
  • Copper-chelating drugs (penicillamine, trientine)
  • Beta-alanine & carnosine supplements
  • Antihistamines (cetirizine, diphenhydramine, loratadine)
  • Levodopa & other large neutral amino acids

Risk & Side Effects

  • Medium: Altered zinc & trace-mineral balance; ammonia elevation & caution in liver disease
  • Low: Gastrointestinal discomfort; histamine-related symptoms
  • Speculative: Metabolic dysfunction & growth effects with excess; neurocognitive effects of very high doses

Monitoring

Marker Target Why
Fasting glucose 70–90 mg/dL Tracks the core metabolic benefit
HbA1c < 5.4% Longer-term glycemic response
Fasting insulin / HOMA-IR Insulin < 6 µIU/mL; HOMA-IR < 1.5 Primary endpoint improved in trials
hs-CRP < 1.0 mg/L Captures the anti-inflammatory effect
Serum zinc 90–120 µg/dL Detects histidine-related zinc depletion
Serum copper 80–155 µg/dL Screens for chelation-related mineral shifts
ALT and AST (liver enzymes) ALT < 25 U/L (men), < 20 U/L (women) Safety screen; contraindicated if liver disease
BUN / ammonia BUN 10–20 mg/dL; ammonia within lab normal Reflects protein/ammonia handling
Complete blood count (hemoglobin) Hgb 13.5–15 g/dL (men), 12–15 g/dL (women) Relevant to red-cell/erythropoiesis role

Cadence: Baseline before starting; recheck at 8–12 weeks, then every 6–12 months on long-term use

Qualitative Assessment

  • Energy levels and exercise tolerance
  • Skin comfort and barrier feel (itch, dryness)
  • Appetite and weight trend
  • Absence of flushing, headache, or stomach upset